In:
Cancer Science, Wiley, Vol. 109, No. 8 ( 2018-08), p. 2599-2610
Abstract:
Nodal cytotoxic molecule ( CM )‐positive peripheral T‐cell lymphoma ( CTL ) has recently been recognized as a clinicopathologically distinct disease. To further characterize this disease, here we compared 58 patients with Epstein‐Barr virus ( EBV )‐negative CTL to 48 patients with EBV ‐positive CTL . The two groups did not differ in histopathology, T‐cell receptor ( TCR ) expression or rearrangement incidences, or survival curves. However, patients with EBV ‐negative CTL less frequently showed hepatic involvement ( P = .007), B symptoms ( P = .020), hemophagocytosis ( P = .024), and detectable CD 4 ( P = .002) and CD 5 ( P = .009). Univariate and multivariate analyses identified three factors that independently predicted favorable survival, onset age 〈 60 years ( P = .002), CD 5 expression ( P = .002), and mixed morphology ( P = .013), TCR αβ was not an independent predictor ( P = .30), but was strongly linked with long survivorship among patients younger than 60 years old. A prognostic model incorporating these factors worked well for prognostic delineation, independently of the International Prognostic Index ( P = .007 vs P = .082) and Prognostic Index for PTCL ( P = .020 vs P = .15). Moreover, this constellation of findings indicated two nodal indolent diseases: CD 5 + TCR αβ (n = 13), and CD 5 + NK ‐cell type lacking TCR expression or clonal TCR γ rearrangement (n = 4). The survival curves for these two groups were significantly superior to others (n = 29, P 〈 .001). These diseases appear to be unique in their indolent clinical behavior, and should be managed differently from other diseases.
Type of Medium:
Online Resource
ISSN:
1347-9032
,
1349-7006
DOI:
10.1111/cas.2018.109.issue-8
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
2115647-5
detail.hit.zdb_id:
2111204-6
Bookmarklink